home.aspx
 
. https://pharmaceutical.report/Resources/Whitepapers/bb7c8120-ab5e-4bee-84cb-a6c624cf2e05_news-release-mda-conference.pdf
infographic
SHARESHARESHARE
SANTHERA TO PRESENT LONG-TERM EFFICACY RESULTS WITH IDEBENONE IN DMD.
Pratteln, Switzerland, April 15, 2019 – Santhera Pharmaceuticals (SIX: SANN) and its collaborating clinical experts present results of long-term efficacy on respiratory function outcomes in idebenonetreated patients with Duchenne muscular dystrophy (DMD) at the 2019 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference held in Orlando, USA, April 13-17, 2019. Posters presented at the MDA conference show consistent long-term efficacy data from two randomized placebo-controlled studies and their extended long-term data collections in patients treated with idebenone (Posters #7 and #9). In addition, new natural history data demonstrates the predictive value of slowing the rate of respiratory function decline on delaying time to initiation of assisted ventilation or death (Poster #11). Collectively, these data support the long-term potential of treatment with idebenone to delay the time to clinically relevant outcomes. DOWNLOAD